Managing Side Effects and Fertility for Premenopausal Patients with Advanced HR+ Breast Cancer

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

This expert podcast includes an engaging discussion among 3 experts on fertility care of patients with breast cancer. This program is designed to help clinicians better recognize and take steps to discuss fertility options in premenopausal patients with hormone receptor-positive (HR+) breast cancer to facilitate care for those women who wish to preserve their reproductive potential without impacting outcomes.

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from TerSera Therapeutics LLC.

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions on How to Receive Credit

• Listen to this podcast in its entirety.
• Go to gotoper.com/credit and enter code: 8243
• Answer the evaluation questions.
• Request credit using the drop-down menu.
• You may immediately download your certificate.

Today’s faculty are:

Rebecca Shatsky, MD

Associate Professor of Medicine
Breast Medical Oncology Co-Team Leader
Scientific Director, Inflammatory and Triple-Negative Breast Cancer Program
UC University of California, San Diego, Comprehensive Breast Health Team
La Jolla, CA

Disclosures: Grant/Research Support: AstraZeneca, Gilead, OBI Pharmaceuticals, Olema Pharmaceuticals; Consultant: AstraZeneca, Daiichi Sankyo, Endeavor Biosciences, Lilly, Novartis, Stemline.

Kelly McCann, MD, PhD

Assistant Professor of Medicine
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA

Disclosures: Grant/Research Support: AstraZeneca, Eli Lilly, Gilead, Merck, Novartis, Olema, Pfizer, Puma Biotechnology, Roche/Genentech, TerSera; Speakers Bureau: Eli Lilly.

Michelle L. Taylor, ANP-BC

Breast Oncology Nurse Practitioner
Wendt Family Breast Cancer Program
Dignity Health Cancer Institute at St. Joseph’s Hospital and Medical Center
Phoenix, AZ

Disclosures: Speakers Bureau: Gilead, Seagen, Stemline Therapeutics.

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Release Date

May 7, 2025

Expiration Date

May 7, 2026